Review by The Pennsylvania State University CiteSeerX Archives
Please cite this article in press as: Fruchart J-C. Peroxisome proliferator-activated receptor-alpha (PPAR): At the crossroads of obesity,
diabetes and cardiovascular disease. Atherosclerosis (2009), doi:10.1016/j.atherosclerosis.2009.03.008
ARTICLE IN PRESS
G Model
ATH-10838; No.of Pages8
Atherosclerosis xxx (2009) xxx–xxx
Contents lists available at ScienceDirect
Atherosclerosis
journal homepage: www.elsevier.com/locate/atherosclerosis
Review
Peroxisome proliferator-activated receptor-alpha (PPAR): At the crossroads
of obesity, diabetes and cardiovascular disease
Jean-Charles Fruchart∗
LaboratoireJ&K ,Inserm UR 545, Université Lille 2, Faculté de Médecine de Lille, Pôle Recherche, Bd du Prof. Leclerc, 59045 Lille Cedex, France
article info
Article history:
Received 2 October 2008
Received in revised form 4 March 2009
Accepted 6 March 2009
Available online xxx
Keywords:
Peroxisome proliferator-activated receptor

Lipoprotein metabolism
Inﬂammation
Vascular function
Cardiovascular
Microvascular
abstract
Cardiovascular disease is the leading cause of morbidity and mortality world-wide. The burden of disease
is also increasing as a result of the global epidemics of diabetes and obesity. Peroxisome proliferator-
activated receptor  (PPAR), a member of this nuclear receptor family, has emerged as an important
player in this scenario, with evidence supporting a central co-ordinated role in the regulation of fatty acid
oxidation,lipidandlipoproteinmetabolismandinﬂammatoryandvascularresponses,allofwhichwould
bepredictedtoreduceatheroscleroticrisk.Additionally,theFenoﬁbrateInterventionandEventLowering
in Diabetes (FIELD) study has indicated the possibility of preventive effects in diabetes-related microvas-
cular complications, although the mechanisms of these effects warrant further study. The multimodal
pharmacological proﬁle of PPAR has prompted development of selective PPAR modulators (SPPARMs)
to maximise therapeutic potential. It is anticipated that PPAR will continue to have important clinical
application in addressing the major challenge of cardiometabolic risk associated with type 2 diabetes,
obesity and metabolic syndrome.
© 2009 Published by Elsevier Ireland Ltd.
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1. Introduction
Cardiovascular disease (CVD) is a major public health con-
cern, as it represents the leading cause of morbidity and mortality
∗ Tel.: +33 3 20 97 42 16; fax: +33 3 20 87 73 60.
E-mail addresses: Jean-Charles.Fruchart@pasteur-lille.fr,
Jean-Charles.Fruchart@univ-lille2.fr.
in the developed world. Within Europe, CVD is responsible for
nearly half (49%) of all mortality, over 4 million cases each year
[1]. Moreover, the burden of CVD is increasing, attributable to
the changing proﬁle of cardiovascular risk, as evident from the
global epidemics of obesity, diabetes (predominantly type 2 dia-
betes) and metabolic syndrome [2,3], the latter characterised
by a cluster of metabolic disorders that predispose to type 2
diabetes mellitus and CVD. These trends are projected to sub-
stantially increase the cost of managing CVD and highlight the
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Fig. 1. Schematic representation of PPAR transcriptional activation. Activation of the PPAR is initiated by binding of an agonist to the ligand binding domain of the nuclear
receptor. Following ligand activation, the PPARs form heterodimers with retinoid X receptor (RXR), another nuclear receptor activated by its own ligand (purported to be
9 cis-retinoic acid). The PPAR–RXR complex subsequently recognises and binds to DNA at sequence-speciﬁc regions on target gene promoters, known as PPAR response
elements (PPRE), thereby activating their expression.
need for concerted efforts to address this increasing burden of dis-
ease.
In the context of this convergence of obesity, diabetes and
CVD,theperoxisomeproliferator-activatedreceptor(PPAR)nuclear
receptor family has received increasing attention. There are three
distinct PPARs – PPAR,P P A R  (also known as PPAR or PPAR/)
and PPAR – each encoded by a separate gene and with spe-
ciﬁc tissue distribution. Experimental evidence shows that the
PPARs play a central role in the regulation of metabolic homeosta-
sis. Activation of the PPAR is initiated by binding of an agonist,
either an endogenous ligand (e.g., fatty acids, eicosanoids, or oxi-
dized phospholipids) or synthetic ligand to the ligand binding
domain of the nuclear receptor. This then forms heterodimers with
retinoid X receptor (RXR), another nuclear receptor activated by
its own ligand (purported to be 9 cis-retinoic acid). The PPAR–RXR
complex subsequently recognises and binds to DNA at sequence-
speciﬁc regions on target gene promoters, known as PPAR response
elements (PPRE), thereby activating their expression (Fig. 1) [4].
Additionally, activation of the PPAR–RXR complex can repress gene
transcription, either by processes independent of DNA-binding via
interference with other signalling pathways or down-regulation of
membrane receptor expression, or by a DNA-dependent process
involving the recruitment of corepressors to PPAR without bound
ligand [4]. Thus, PPAR can regulate the expression of multiple gene
cassettes, thereby offering the opportunity for a novel integrated
co-ordinated response across different organs and cells.
Despite their serendipitous discovery and clinical use in the
treatmentofdyslipidemiaforoverthreedecades,elucidationofthe
pharmacological proﬁle of activity of the ﬁbrates, PPAR agonists,
is more recent. Evidence clearly supports a central role for PPAR
intheregulationoflipidandlipoproteinmetabolism,inﬂammation
and vascular function, which impacts on the process of atherogen-
esis. Together, these ﬁndings have led to renewed interest in PPAR
as a therapeutic target.
2. PPAR and lipid metabolism
The effects of PPAR on lipids and lipoproteins are summarised
in Fig. 2. Activation of PPAR leads to increased tissue-speciﬁc
expression of key genes involved in fatty acid uptake and -
oxidation. This includes acyl-Coenzyme A synthetase, an enzyme
which plays a key role in esteriﬁcation of fatty acids thereby pre-
venting their efﬂux from cells, in the liver and kidney [5], and
carnitine palmitoyltransferase type 1 (CPT-1), a pivotal enzyme
involved in fatty acid catabolism within mitochondria in metabol-
ically active tissue such as the heart, skeletal muscle and brown
adipose tissue, which contains a PPRE in its promoter region. The
net effect of this is reduction in the availability of free fatty acids for
synthesisandsecretionofvery-low-densitylipoproteins(VLDL)[4].
2.1. Impact on triglyceride and low-density lipoprotein (LDL)
metabolism
PPAR activation decreases triglycerides (TG) by increasing free
fatty acid -oxidation, hepatic lipoprotein lipase expression [6],
and expression of apolipoprotein V (apoV) [7], and by decreasing
expression of apolipoprotein CIII (apoCIII) [8]. The mechanism by
which PPAR activation represses apoCIII transcription has yet to
elucidated. In vitro studies imply repression of apoCIII expression
via interaction with a PPRE in the Rev-erb- promoter, given that
mice deﬁcient in this protein exhibit increased plasma concentra-
tions of TG and apoCIII [9]. Furthermore, whether apoCIII affects TG
metabolism in vivo is contentious. Some studies showed an effect
in normolipidemic subjects [10], whereas in other studies apoCIII
affected TG metabolism only when associated with lipoproteins at
concentrationsnotfoundinvivo.IncreasesinthenumberandapoC-
III content of VLDL particles also have adverse consequences for
other lipoprotein subspecies, contributing to an increase in small,
dense LDL particles. PPAR activation promotes a change in the
distribution proﬁle of LDL particles, decreasing the levels of athero-
genicdenseLDL-cholesterol,withpoorafﬁnityfortheLDLreceptor,
while increasing large buoyant LDL particles, which have a high
afﬁnity for this receptor [11].
2.2. PPAR˛, high-density lipoprotein (HDL) metabolism and
reverse cholesterol transport
In addition, PPAR regulates HDL metabolism by (1) stimu-
lating hepatic expression of apoA-I and apoA-II and thus raising
HDL production in the liver [12], (2) promoting HDL-mediated
cholesterol efﬂux from macrophages, via enhanced expression of
scavengerreceptor-BI[13]andtheATP-bindingcassettetransporter
A1 (ABCA1) [14], and (3) inhibiting cellular cholesteryl ester for-
mation activity, thereby limiting accumulation of cholesteryl esterPlease cite this article in press as: Fruchart J-C. Peroxisome proliferator-activated receptor-alpha (PPAR): At the crossroads of obesity,
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Fig. 2. Fibrates regulate lipid metabolism by controlling the expression of PPAR genes. Activation of PPAR leads to increased expression of genes involved in fatty acid
uptake and -oxidation, as well as those responsible for the expression of hepatic lipoprotein lipase and apolipoprotein V (apoV) and decreased expression of apolipoprotein
CIII (apoCIII). The net effects of these actions are increases in high-density lipoprotein (HDL) production, very-low-density lipoprotein (VLDL) clearance and low-density
lipoprotein (LDL) particle size and decreases in VLDL production and LDL particle concentration.
in vascular macrophages and preventing foam cell formation [15],
as well as contributing to enhanced efﬂux of free cholesterol to
extracellular receptors [14,15]. As well, PPAR activation regulates
processes controlling cholesterol mobilisation that are upstream
of cholesterol efﬂux, leading to enhanced availability of plasma
membrane cholesterol for cholesterol efﬂux [16], which together
with regulation of ABCA1 and SR-BI expression, stimulate reverse
cholesterol transport.
3. PPAR, inﬂammation and atherosclerosis
Mechanistically, PPAR activation may inﬂuence the develop-
ment of atherosclerosis via indirect effects on glucose and lipid
homeostasis in adipose tissue, skeletal muscle and the liver. Addi-
tionally, PPAR may have a direct effect on inﬂammation and
atherosclerosis, by modiﬁcation of the transcription factors nuclear
factor-B (NF-B) and activator protein-1 (AP-1).
3.1. PPAR˛ and early atherogenesis
PPAR is expressed in inﬂammatory cells involved in the
process of atherogenesis, such as monocytes, macrophages and
lymphocytes [17–19] implying a regulatory role in the early stages
of atherosclerosis. PPAR activators inhibit cytokine-induced
expression of vascular cell-adhesion molecule-1 (VCAM-1) and
intercellular adhesion molecule-1 (ICAM-1), both of which play a
critical role in the recruitment of leukocytes and monocytes to the
atherosclerotic lesion, by down-regulation at the transcriptional
level [18], mediated in part by inhibition of the NF-B signalling
pathway [17,18,20]. The effect of PPAR activation on expression
of monocyte chemoattractant protein-1 (MCP-1) is less clear; with
studies reporting stimulation of synthesis [21], or reduction in C-
reactive protein (CRP)-induced expression [22].P P A R  ligands also
repress thrombin-induced expression of endothelin-1 (ET-1), by
negatively interfering with the AP-1 signalling pathway [23].
3.2. PPAR˛ and local cellular inﬂammation
Cytokines such as tumour necrosis factor- (TNF-), inter-
leukins and interferon-, which are released from T lymphocytes
during the initiation of a chronic inﬂammatory response, play
a critical role in cellular immunity, and contribute to the early
development of plaque. Therefore, repression of inﬂammation by
decreasing cytokine release could be very important in modulating
the cascade of responses in atherosclerosis.
Cytokine imbalance associated with the metabolic syndrome
is thought to be the mechanism driving the development of
non-alcoholic fatty liver disease (NAFLD) (Fig. 3). TNF- pro-
motesinsulinresistanceandliverinﬂammationandsuppressesthe
expressionandsecretionofadiponectininadipocytes,althoughthe
underlyingmechanismispoorlyelucidated.TNF-polymorphisms
have been associated with increased susceptibility genotype for
insulin resistance, NAFLD, and steatohepatitis [24].
Activation of PPAR inhibits the expression of genes coding for
a range of acute-phase proteins and inﬂammatory cytokines, such
as interleukin-6 (IL-6), C-reactive protein (a complement activa-
tor and inducer of MCP-1 expression), ﬁbrinogen and TNF- [25],
which implies an anti-inﬂammatory role for PPAR. Control of the
expression of these inﬂammatory cytokines is exerted by inter-
ference with the NF-B and AP-1 inﬂammatory pathways at the
transcriptional level [20,26]. The clinical relevance of these ﬁnd-
ings is supported by studies showing that fenoﬁbrate treatment
decreasedplasmaconcentrationsofIL-6andTNF-inpatientswith
dyslipidemia[27].Additionally,giventhathepaticPPARactivation
suppresses expression of hepatic inﬂammatory mediators includ-
ing TNF- and reduces hepatic fat accumulation in the liver during
thedevelopmentoffattyliverdisease[28],suggestsapotentialrole
in preventing steatosis and subsequent progression to NAFLD. In
support of this, preliminary data show that fenoﬁbrate treatment
improved metabolic syndrome and liver function tests in patients
with NAFLD [29].
3.3. PPAR˛, plaque stability and thrombosis
Advanced atherosclerotic plaques are characterised by a core
of extracellular lipid droplets, cellular debris and foam cells, sur-
roundedbyaﬁbrouscapofsmoothmusclecellsandacollagen-rich
matrix. Progression from a stable to unstable plaque is depen-
dentlargelyonthebalancebetweenproductionanddegradationof
the extracellular matrix in the ﬁbrous cap. Experimental evidencePlease cite this article in press as: Fruchart J-C. Peroxisome proliferator-activated receptor-alpha (PPAR): At the crossroads of obesity,
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Fig. 3. Cytokine imbalance associated with the metabolic syndrome resulting in underlies the development of non-alcoholic fatty liver disease. The development of non-
alcoholicfattyliverdisease(NAFLD)isassociatedwithimbalancebetweenthepro-inﬂammatoryactionsresultinginincreasedexpressionoftumournecrosisfactor-(TNF-)
and anti-inﬂammatory actions resulting in reduced adiponectin expression. This in turn promotes insulin resistance, inﬂammation (non-alcoholic steatohepatitis, NASH) and
subsequently steatosis and cell death (NAFLD).
suggests that PPAR ligands may modulate this balance by down-
regulation of LPS-induced secretion of matrix metalloproteinase-9
(MMP-9) [30].P P A R  ligands also enhance macrophage apoptosis,
probably by negative interference with the anti-apoptotic NF-B
pathway [31], although the clinical relevance of this effect is not
certain.
Additionally, PPAR activation may impact on the processes
involvedinatherothrombosissubsequenttoplaquerupture.Exper-
imental studies show that expression of tissue factor in human
monocytes and macrophages is down-regulated by activation of
PPAR ligands, suggesting a potential mechanism whereby ﬁbrates
may inﬂuence atherothrombosis in patients with vascular disease
[32].P P A R  activation may also modulate the expression of plas-
minogen activator inhibitor type 1 (PAI-1), a member of the serine
protease inhibitor family which limits ﬁbrinolysis and promotes
thrombosis, although results are conﬂicting, with studies showing
increased PAI-1 expression with cloﬁbrate or bezaﬁbrate [33], but
a decrease with fenoﬁbrate or gemﬁbrozil [34].
4. PPAR and vascular function
While the role of PPAR in the regulation of lipid metabolism
and inﬂammation is now well recognized (Table 1), recent evi-
dencealsoindicatesthatPPARisimportantincontrollingvascular
smooth muscle cell proliferation. Activation of smooth muscle cell
Table 1
Summary of effects of PPAR activation in improving vascular function.
Response Mediators
↓ Cell recruitment and activation ↓MCP-1, VCAM-1, ICAM-1 and
chemokines
↓ Inﬂammatory response ↓TNF-, interleukins, CRP, VCAM-1,
tissue factor, ﬁbrinogen
↑Cholesterol efﬂux, ↓ foam cell formation ↑ABCA1, SR-BI, CD36, ↓SR-A
↓ Vasoconstriction and cell migration ↓ET-1, MMP, thromboxane
↓ Thrombosis, ↑ plaque stability ↓MMP-9, PAF, tissue factor
ABCA1 ATP-binding cassette transporter A1; CRP C-reactive protein; CD36 cluster
of differentiation 36; ET-1 endothelin-1; ICAM-1 intercellular adhesion molecule-1;
MCP-1 monocyte chemoattractant protein-1; MMP matrix metalloproteinase; SR-A
scavenger receptor A; SR-BI scavenger receptor-BI, TNF- tumour necrosis factor-;
VCAM-1 vascular cell-adhesion molecule-1.
proliferation is a key event in the development of atherosclerotic
complications. In response to vascular injury, smooth muscle cells
migrate into the intima of the arterial wall, where they subse-
quently proliferate and synthesize extracellular matrix, resulting
in intimal hyperplasia. During this process, smooth muscle cells
undergo phenotypic changes from a differentiated, contractile qui-
escent state (G0 phase of the cell cycle), to a synthetic, embryonic,
proliferative state (S phase).
In vitro studies using both human and mouse primary aor-
tic smooth muscle cells show that PPAR inhibits smooth muscle
cell-cycle progression at the G1/S transition, an effect attributed
to induction of the cyclin-dependent kinase inhibitor and tumour
suppressorgenep16INK4a (p16).Thisinturnresultsinthesequestra-
tion of cyclin-dependent kinase 4 (CDK4) and subsequent decrease
in CDK4-mediated phosphorylation, thereby providing a molecu-
lar mechanism whereby PPAR directly interferes with cell-cycle
progression [35]. In an in vivo mouse model of mechanical carotid
artery injury, p16 deﬁciency was associated with enhanced smooth
muscle cell proliferation underlying intimal hyperplasia, and this
effect was markedly enhanced in PPAR deﬁcient mice compared
with wild type (PPAR+/+) mice. Moreover, treatment of PPAR
wild type mice with fenoﬁbrate substantially reduced intimal
hyperplasia (Fig. 4) [35]. Together these ﬁndings suggest potential
therapeutic application for PPAR in preventing restenosis either
via systemic administration or in coated stents.
5. The role of PPAR in obesity
Increasing evidence suggests that PPAR may have a role in the
management of obesity, especially central obesity associated with
insulin resistance syndromes, given its involvement in the regula-
tion of fatty acid oxidation, lipid metabolism and inﬂammation.
Stimulation of -oxidation by PPAR activation (see Section 2),
implies a mechanism for decreasing tissue lipid content, thereby
preventing lipid accumulation. Experimental studies also indicate
the involvement of PPAR in the transcriptional response to fast-
ing, as evident by the development of steatotic liver and heart and
marked increases in free fatty acid levels, indicative of inhibition
of fatty acid uptake and oxidation, in mice deﬁcient in PPAR [36].
PPAR activation may also have a beneﬁcial effect on insulin sen-
sitivity, by reducing plasma TG levels and adiposity [37].Please cite this article in press as: Fruchart J-C. Peroxisome proliferator-activated receptor-alpha (PPAR): At the crossroads of obesity,
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Fig. 4. Animal studies using a mouse model show that treatment with fenoﬁbrate inhibits neointima formation after mechanical carotid injury. Data from Gizard et al. [35].
Left carotid artery injury was performed on PPAR−/− (n=6 )o rP P A R +/+ Sv/129 mice treated (n=5 )o rn o t( n=8) with fenoﬁbrate. The topographic pattern of intima–media
(I/M) area ratio 3 weeks after injury was markedly enhanced in PPAR−/− mice but reduced in PPAR+/+ mice treated with fenoﬁbrate (*p≤0.05 versus PPAR+/+ wild
type mice not treated with fenoﬁbrate for each comparison). Values were reported as mean±S.E.M. of the I/M ratios measured on Masson’s trichrome-stained sections
at the indicated distances from the junction between the external and internal branches of the left carotid artery. Consistent with this, representative carotid sections of
uninjured right and injured left carotids at 50m from the junction stained with Masson’s trichrome (top panel), immunostained for SMC (-actin staining, middle panel)
or for proliferation marking (proliferating PCNA immunostaining to identify cells in S phase, bottom panel) also showed marked reduction in PPAR+/+ mice treated with
fenoﬁbrate. Scale bars: 100M. SMC smooth muscle cells.
Additionally, PPAR activation may protect against chronic
inﬂammation associated with obesity, by down-regulation of gene
expressionofinﬂammatorymarkersandattenuatinginﬂammation
in adipose tissue, supported by results in a mouse model [38].I n
PPAR deﬁcient mice, which exhibit high adiposity together with
an inﬂammatory state, there was evidence of down-regulation of
mRNA expression of insulin gene transcription factors, reduction
of pancreatic function, together with down-regulation of adipocyte
mRNA of pro-inﬂammatory mediators including MCP-1, TNF- and
IL-6 [39]. Furthermore, PPAR activation may play a role in ame-
lioration of obesity-induced insulin resistance in obese diabetic
micevianovelmechanismsincludingsuppressionofadiposehyper-
trophy and macrophage inﬁltration in white adipose tissue and
increasingtheactionofadiponectinbyupregulationofadiponectin
receptor expression [40]. Further work is needed to deﬁne whether
the anti-inﬂammatory effects of PPAR in white adipose tissue are
caused by direct or indirect mechanisms.
6. PPAR in the setting of increased cardiometabolic risk
GiventhatPPARisacentraltargetinﬂuencingvascularfunction
via effects on cholesterol homeostasis and inﬂammation control
in macrophages, ET-1 signalling in endothelial cells and vascular
remodelling in smooth muscle cells, highlights a cardioprotective
role for PPAR activators, especially in patients at increased car-
diometabolic risk,
Amongpeoplewithtype2diabetesand/ormetabolicsyndrome,
an atherogenic lipid proﬁle characterized by elevated TG and low
plasma levels of HDL cholesterol, usually with a preponderance of
small, dense LDL particles, is common. Lowering LDL-cholesterol
with statins is the primary focus of lipid management for preven-
tion CVD in patients at increased cardiometabolic risk, supported
by an extensive evidence base of large prospective trials [41].H o w -
ever, despite intensive LDL-lowering (from 100mg/dL to 70mg/dL)
there remains substantial residual risk of cardiovascular events,
associated with low HDL cholesterol (<37mg/dL) [42] or elevated
TG (>200mg/dL) [43]. These data highlight a potential need for
additional therapeutic intervention.
7. Macrovascular beneﬁts of PPAR agonists
In this setting, PPAR agonists represent a logical therapeutic
choice, supported by clinical trial evidence showing improvement
in lipid proﬁles and clinical outcome beneﬁts associated with
ﬁbrate treatment (Table 2) [44–51]. Cardiovascular risk reduction
with ﬁbrate therapy appeared to be further enhanced in patients at
increased cardiometabolic risk due to diabetes, as evident by 32%
reductioninmajorcardiovascularevents,acompositeofCHDdeath,
nonfatal MI and stroke versus 22% in all study patients with gem-
ﬁbrozil treatment in the Veterans Affairs HDL Intervention Trial
(VA-HIT) [44,45]. As well as those with hypertriglyceridemia or
metabolic syndrome had risk reductions of 39.5% and 25%, respec-
tively, in fatal or nonfatal MI or sudden death versus 9.4% in all
patients with bezaﬁbrate treatment in the Bezaﬁbrate Infarction
Prevention study (Table 2) [46,47].
In the primary prevention setting, post hoc analysis of the
Helsinki Heart study showed enhanced clinical beneﬁt with gem-
ﬁbrozil treatment in patients with features of the metabolic
syndrome(baselineTG>200mg/dL,HDLcholesterol<40mg/dLand
BMI>26kg/m2) with 78% reduction in coronary risk versus 34%
reduction in all patients (Table 2) [48,49]. Furthermore, in the
Fenoﬁbrate Intervention and Event Lowering in Diabetes (FIELD)
study in 9795 patients with well-controlled, type 2 diabetes and
mainlywithoutpriorCVD(78%),thepresenceofmarkedlyelevated
TG (>200mg/dL) together with low HDL cholesterol (<40mg/dL
in men and <50mg/dL in women), was associated with enhanced
reduction in risk for total cardiovascular events (27%, p=0.005, ver-
sus 11%, p=0.035 in all patients) [50,51]. It should be noted that
fenoﬁbrate treatment did not have a signiﬁcant effect on the pri-
maryendpoint(nonfatalMIorCHDdeath,−11%,p=0.16),although
this may have been attributable to the confounding inﬂuence of
an excess of drop-in non-study lipid-modifying therapy, predom-
inantly statins, in the placebo group (17% versus 8%, averaged
over the study) [50]. Coronary angiographic trials generally sup-
port these ﬁndings of the ﬁbrate outcome studies with signiﬁcant
reduction in atheroma progression in coronary or carotid arteries
associated with ﬁbrate treatment [52].Please cite this article in press as: Fruchart J-C. Peroxisome proliferator-activated receptor-alpha (PPAR): At the crossroads of obesity,
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Table 2
Effects of ﬁbrates on macrovascular outcomes in patients at increased cardiometabolic risk.
Trial End point Patients Absoluteeventrate(%) Reduction in
relative risk (%)
p-value
Control Fibrate
HHS [48,49] Fatal+nonfatal MI and CHD death (a) All patients (4081 men without
CHD+non-HDL-C ≥200mg/dL)
4.1 2.7 34 <0.02
(b) Met Syn (TG ≥204 mg/dL HDL-C <40mg/dL,
BMI>26kg/m2)
NR NR 78 0.002
NR NR
VA-HIT [44,45] Nonfatal MI+CHD death+stroke (a) All patients (2531 men with CHD and low
HDL-C (<40mg/dL)
26.0 20.4 24 <0.001
(b) Diabetes
36.1 24.5 32 0.004
(c) Elevated TG (≥150mg/dL) 27.0 20.0 27 0.01
BIP [46,47] Fatal or nonfatal MI or sudden death (a) All patients (3090 men and women with
previous MI or angina)
15.0 13.6 7.3 0.24
(b) Elevated TG (>200mg/dL)
19.7 12.0 39.5 0.02
(c) Met Syna 18.4 14.1 25.0 0.03
FIELD [50] Nonfatal MI+CHD death (a) All patients (9795 men and women with
type 2 diabetes)
5.9 5.2 11 0.16
Total CVD events 13.9 12.5 11 0.035
Total CVD events (b) Met Synb 17.8 13.5 26 0.01
CHD, coronary heart disease; CVD, cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; MI, myocardial infarction; Met Syn, metabolic syndrome; NR, not
reported; BIP, Bezaﬁbrate Infarction Prevention study; FIELD, Fenoﬁbrate Intervention and Event Lowering in Diabetes study; HHS, Helsinki Heart study; VA-HIT, Veterans
Affairs HDL Intervention Trial.
a Deﬁnedbyleastthreeofthefollowing:fastingglucose≥110mg/dLorcurrentuseoforalhypoglycemictreatment,TG≥150mg/dL,HDL-C<40mg/dLinmenand<50mg/dL
in women, systolic blood pressure ≥130mmHg or diastolic blood pressure ≥85mmHg or body mass index ≥28.0mg/kg2.
b Deﬁned as HDL cholesterol <40mg/dL in men and <50mg/dL in women and TG≥200mg/dL.
However, changes in the lipoprotein–lipid proﬁle only partially
explaintheclinicaloutcomebeneﬁtsofﬁbrates.TheVA-HITinvesti-
gatorsdemonstratedreductioninCRP,amarkerofinﬂammation,in
men with high fasting insulin levels in whom CVD risk was reduced
by34%[53].Thisﬁndingisalsosupportedbyevidenceof74%reduc-
tion in high-sensitivity CRP levels in dyslipidemic obese subjects
[54]. These data imply that clinical outcomes beneﬁts associated
with ﬁbrate treatment result not only from improvement in the
plasma lipoprotein and lipid proﬁle, but also the chronic low-grade
inﬂammatorystateassociatedwithincreasedcardiometabolicrisk.
7.1. Combination therapy: which PPAR˛ agonist?
Thus, these data provide a rationale supporting the use of
ﬁbrates as add-on therapy to statins in patients at increased
metabolic risk, characterised by marked dyslipidemia (elevated TG
and low HDL cholesterol), supported by clinical studies such as
SAFARI(SimvastatinplusFenoﬁbrateforcombinedhyperlipidemia)
[55]. Of the available ﬁbrates, fenoﬁbrate is probably the most
appropriatePPARagonistforcombinationwithastatin,supported
by analysis of safety surveillance data from the US Food and Drug
Administration’sAdverseEventsReportingSystem(AERS)database
(1998–2002), which reported a 15-fold increase in the incidence of
cases of rhabdomyolysis and 33-fold increase in the incidence of
cases of myopathy (without rhabdomyolysis) associated with pre-
scription of gemﬁbrozil and a statin (excluding cerivastatin, now
discontinued) compared with fenoﬁbrate plus statin [56]. This may
be explained on the basis of in vitro experimental studies which
report that gemﬁbrozil competes with the statin for metabolism
by UDP-glucuronyl transferases, in turn increasing plasma levels
of the statin, whereas fenoﬁbrate is metabolized by a different
family of glucuronyl transferases and is therefore much less likely
to increase statin plasma concentrations in vivo [57]. Supportive
data from the FIELD study show that none of 890 patients who
receivedthecombinationoffenoﬁbrateplusstatindevelopedrhab-
domyolysis during the study [50]. Clearly, this strategy warrants
evaluation, currently being addressed by the lipid treatment proto-
col of the ongoing Action to Control Cardiovascular Risk in Diabetes
(ACCORD) study, which is studying the combination of simvas-
tatin plus fenoﬁbrate in about 5500 patients with type 2 diabetes
and existing or at risk for clinical CVD. Data are anticipated in
2009.
8. Microvascular beneﬁts of PPAR
As type 2 diabetes prevalence has increased, so too has the
burden of diabetes-related microvascular complications, includ-
ing diabetic retinopathy, nephropathy and neuropathy. While the
STENO-2 study showed the beneﬁts of intensive multifactorial
treatment (targeting blood pressure, blood glucose and lipids in
addition to treatment with an angiotensin converting enzyme
inhibitor, low-dose aspirin and lifestyle modiﬁcation) over conven-
tional treatment in reducing the risk of both macrovascular and
microvascular complications, there remains a residual microvascu-
larrisk;34%ofthesepatientsdevelopedretinopathy,20%developed
nephropathy and peripheral neuropathy progressed in 50% of
patients over the study period [58].
Findings from the FIELD study suggest that fenoﬁbrate may
have a preventive role in reducing the risk of diabetes-related
microvascular complications, speciﬁcally ﬁrst laser treatment for
diabetic retinopathy (−31%, p=0.0002) [59], progression of albu-
minuria (−15%, p=0.002) [50] and non-traumatic lower-extremity
amputation (−38%, p=0.04), predominantly microvascular ampu-
tation (−47%, p=0.025) [67]. The preventive effects of fenoﬁbrate
treatment on retinopathy applied similarly to both maculopathy
(−31%, p=0.002) and proliferative retinopathy (−30%, p=0.015).
Patientswithoutretinopathyhistoryderivedgreaterbeneﬁt(−39%,
p=0.0008 reduction in ﬁrst laser therapy) than those with (−23%,
p=0.06) Placing these data in a clinical context, 17 patients with
pre-existing retinopathy and 90 without known prior eye disease,
would need to be treated with fenoﬁbrate for 5 years to avoid ﬁrst
laser therapy in one patient [59]. Additionally, the FIELD Ophthal-
mology substudy (n=1012) which used serial fundus photography
to assess retinopathy progression, showed that fenoﬁbrate treat-
ment led to signiﬁcant reduction in the progression of disease in
patients with pre-existing retinopathy (−79%, p=0.004), althoughPlease cite this article in press as: Fruchart J-C. Peroxisome proliferator-activated receptor-alpha (PPAR): At the crossroads of obesity,
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ﬁndingswerenotstatisticallysigniﬁcantwhenallpatientsincluded
in the substudy were evaluated. The effects of fenoﬁbrate did not,
however, appear to be related to the degree of glycemic or lipid
control, or concomitant medication [59].
Experimental evidence implies that PPAR activation may play
a role in the aetiology of these microvascular effects by inhibit-
ing angiogenesis via effects on expression of vascular endothelial
growth factor (VEGF)-receptor 2 and VEGF-receptor signalling [60],
as well as proliferation of capillary endothelial cells induced by
VEGF and ﬁbroblast growth factor [61]. Additionally, reduction of
plasmalevelsofinsulin-likegrowthfactor-1(IGF-1)associatedwith
PPAR activation may reduce neovascularisation associated with
proliferative retinopathy, stimulated by protein kinase B and the
NF-B and AP-1 pathways [62]. In vitro evidence also suggests that
fenoﬁbrate may regulate retinal endothelial cell survival via a novel
mechanism dependent on adenine monophosphate-activated pro-
tein kinase (AMPK) activity [63]. The mechanism(s) of fenoﬁbrate’s
effectinimprovingalbuminuriaprogressionisstillunderinvestiga-
tion, although reduction in mesangial cell hypertrophy and matrix
expansion, together with renal inﬂammation and glomerular cell
apoptosisassociatedwithPPARactivationmaybeimplicated[64].
9. Future directions
To maximise therapeutic potential, future developments in the
area of PPAR are aimed at developing selective agents with tissue-
selective and targeted gene-selective activities, i.e. selective PPAR
modulators (SPPARMs). The validity of this concept is supported by
demonstration of differential PPAR-dependent effects of gemﬁ-
brozil and fenoﬁbrate on hepatic apoA-I expression. Whereas both
fenoﬁbrate and gemﬁbrozil increase HDL cholesterol levels, fenoﬁ-
brate also efﬁciently increases apoA-I levels, whereas gemﬁbrozil
has little or no effect in man. In vitro pharmacological proﬁling
showsthatfenoﬁbrateactsasafullagonistofPPAR,whereasgem-
ﬁbrozil acts as a partial agonist due to differential recruitment of
coactivators to the promoter region [65].
The SPPARM concept has been used to select and develop new
PPAR activators, based on pharmacological proﬁling assays, gene
proﬁling and microarray and in vivo assays to evaluate effects
on lipid and glucose metabolism, anti-inﬂammatory and vascular
effects, as well as potential side effects. A promising SPPARM devel-
oped using this process is GFT505, a potent partial PPAR agonist
with SPPARM characteristics. Compared with fenoﬁbrate, GFT505
b e h a v e sa saP P A R -selective SPPARM modulator with improved
lipid-modifying activity (lowering TG and cholesterol and raising
HDL cholesterol and apoA-I to a greater extent than comparable
doses of fenoﬁbrate). This lipid-modifying activity translated to
50% reduction in atherosclerotic plaque in an in vivo animal model.
Ongoing clinical trials are investigating the potential of GFT505 for
management of dyslipidemia associated with abdominal obesity
[66]. These ﬁndings highlight the potential of these novel PPAR
agonists in the management of cardiometabolic risk.
10. Conclusion
Experimental evidence supports the mechanistic view that
PPAR represents a central target regulating fatty acid oxidation,
lipid and lipoprotein metabolism and inﬂammatory and vascular
responses, all of which would be predicted to decrease atheroscle-
rotic risk. Anti-inﬂammatory activities demonstrated for PPAR
also suggest potential therapeutic application for the manage-
ment of NAFLD. The use of PPAR activators such as ﬁbrates
therefore offers the possibility of co-ordinated modiﬁcation to
repress inﬂammatory mechanisms and limit the development of
atherosclerosis in individuals with insulin-resistant conditions,
supported by clinical outcomes studies. Moreover, ﬁndings from
the FIELD study also indicate a preventive role for the use of fenoﬁ-
brate for attenuation of residual diabetes-mediated microvascular
risk.
Elucidation of the effects of PPAR has prompted further evolu-
tion to novel selective PPAR agonists using the SPPARM concept.
It is anticipated that PPAR will continue to have important ther-
apeutic application in the management of cardiometabolic risk
associated with type 2 diabetes and metabolic syndrome, in par-
ticular in addressing the major challenge of residual vascular
risk.
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